May 20th 2024
"We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Dr. Tran on enzalutamide plus salvage radiation therapy in biochemically recurrent prostate cancer
January 30th 2023The phase 2 SALV-ENZA trial explored whether the addition of enzalutamide to salvage radiation therapy could improve outcomes in patients with high-risk, PSA-recurrent prostate cancer after radical prostatectomy.
Trial to evaluate TKI and abiraterone treatment combination for prostate cancer
January 19th 2023“If outcomes are improved for patients who take this combination — or in patients whose cancer is still progressing after being treated with hormone-based chemotherapy alone — this could be a big step forward in caring for these patients," says Moshe Ornstein, MD, MA.
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
January 18th 2023Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Factors for Consideration When Selecting Treatments for Patients with mCRPC
January 18th 2023Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.
How testosterone therapy use in men with prostate cancer has evolved
January 5th 2023Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who have been treated with prostatectomy or cryosurgery. But these men should be closely monitored, they stress.